v3.26.3
SEGMENT INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Information about Reportable Segments and Reconciliation of Segment Operating Income and Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
Segment Net Sales
United States$1,007.6 $907.5 $2,948.7 $2,636.1 
Europe414.6 387.9 1,296.8 1,107.9 
Japan92.0 90.1 279.0 267.2 
Rest of World201.3 167.6 580.6 486.8 
Total segment net sales$1,715.5 $1,553.1 $5,105.1 $4,498.0 
Cost of Sales
United States$182.8 $167.1 $540.0 $480.6 
Europe93.8 82.4 280.8 249.4 
Japan15.2 13.3 44.8 39.2 
Rest of World53.4 40.8 156.2 124.5 
Total segment cost of sales$345.2 $303.6 $1,021.8 $893.7 
Selling, general, and administrative expenses
United States$165.6 $140.2 $484.4 $409.1 
Europe76.0 70.0 224.1 217.6 
Japan18.8 17.9 51.2 52.8 
Rest of World53.3 49.5 151.3 139.9 
Total segment selling, general, and administrative expenses$313.7 $277.6 $911.0 $819.4 
Other Segment Items
United States$0.5 $0.7 $2.0 $1.9 
Europe29.0 28.9 109.0 35.8 
Japan(10.0)(0.9)(24.9)(5.7)
Rest of World(7.3)(4.7)(21.9)(21.8)
Total other segment items (a)
$12.2 $24.0 $64.2 $10.2 
Segment Operating Income
United States$658.7 $599.5 $1,922.3 $1,744.5 
Europe215.8 206.6 682.9 605.1 
Japan68.0 59.8 207.9 180.9 
Rest of World101.9 82.0 295.0 244.2 
Total segment operating income$1,044.4 $947.9 $3,108.1 $2,774.7 
_______________________________________________________________________________
(a)    Other segment items include research and development expenses and foreign currency.
The table below presents a reconciliation of segment operating income to consolidated pre-tax income (in millions):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
Pre-tax Income Reconciliation
Segment operating income$1,044.4 $947.9 $3,108.1 $2,774.7 
Unallocated amounts:
Corporate items(533.7)(510.5)(1,566.8)(1,501.9)
Restructuring charges, separation costs, and other(10.7)(0.1)(10.7)(8.5)
Impairment of intangible and long-lived assets(220.2)(40.0)(220.2)(40.0)
Certain litigation (insurance recovery) expenses, net12.7 (90.4)(30.7)(116.8)
Change in fair value of contingent consideration liabilities— 12.5 — 12.5 
Foreign currency6.6 (12.3)10.2 (6.9)
Consolidated operating income299.1 307.1 1,289.9 1,113.1 
Non-operating income (expense)64.1 41.3 52.1 69.4 
Consolidated pre-tax income$363.2 $348.4 $1,342.0 $1,182.5 
Schedule of Enterprise-Wide Information
Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
Net Sales by Major Product Group
Transcatheter Aortic Valve Replacement$1,241.6 $1,149.9 $3,697.2 $3,327.4 
Transcatheter Mitral and Tricuspid Therapies209.5 145.2 583.2 394.9 
Surgical
264.4 258.0 824.7 775.7 
$1,715.5 $1,553.1 $5,105.1 $4,498.0